C. difficile infection

and an effective way to combat it

with HospBiome and DiffBiome MTT capsules

Reducing the number of infections

with the help of a properly formulated microbiota extract

The appearance and overgrowth of the toxin-producing variant of the bacterium Clostridioides (Clostridium) difficile (hereinafter: C. diff.) most commonly occur following prolonged antibiotic therapy, hospitalization, or conditions that weaken immune defense. Due to the disruption of the healthy microbiota balance, the bacterium spreads, causing fever, abdominal pain, vomiting, and diarrhea.

Treatment of Overgrowth is increasingly performed using Microbiota Transfer Therapy (MTT) due to rising antibiotic resistance and the need to restore microbiota balance. In cases of previously confirmed infection, treatment can begin immediately based on symptoms.

Our DiffBiome and HospBiome capsules offer an effective solution for treating C. diff. infections in both home and hospital settings. We provide expert guidance in selecting the most appropriate capsule treatment and in reducing the number of treatments required in hospital environments.

Patient Information Leaflet

Capsules

Treatment of C. diff. Infection

with MicroBiome Bank MTT Capsules

Specifically for the treatment of C. diff. in hospitalized patients
Recommended for patients in whom antibiotic therapy has not provided adequate results or who have experienced multiple recurrences of CDI
Minimum order quantity: 120 packaging units (20 treatment units)

For the home treatment of recurrent Clostridioides (Clostridium) difficile infection that does not respond to antibiotic therapy
Recommended for patients who no longer require hospital treatment but are still struggling with the infection
Minimum order quantity: 1 packaging unit (1 box)

Comparative Analysis of MTT and Antibiotics

Medical background

Clostridium difficile infection (CDI) poses a significant challenge in modern healthcare, requiring effective and cost-efficient treatment strategies. Below we aim to provide a comprehensive analysis of two primary treatment modalities: Microbiome Treatment Therapy by FMT and antibiotics. Traditional antibiotic therapy, while many times effective, has been linked to high recurrence rates, leading to the exploration of alternative treatments such as MTT.

MicroBiota Treatment Therapy (MTT)

Pros

Cons

High Cure Rates: MTT has demonstrated superior efficacy in treating recurrent CDI, with cure rates exceeding 86%.
Microbiome Restoration: MTT restores the balance of gut microbiota, promoting long-term resilience against CDI recurrence.
Reduced Antibiotic Dependency: MTT reduces reliance on antibiotics, potentially mitigating antibiotic resistance concerns.
Long Term Financial Benefits: MTT may have higher initial costs due to donor screening, laboratory testing, and procedural requirements, but due to its higher cure rates, application may lead to long-term cost savings by reducing the need for repeated courses of antibiotics and hospital readmissions.

Limited Standardization: Due to the nature of MTT, the microbiome of each donor changes every day, every hour, and therefore, unlike drugs, it cannot be standardised. MTT lacks standardized protocols, leading to variability in clinical outcomes.
Risk of Infection Transmission: There is a minimal risk of transmitting infections from the donor to the recipient, emphasizing the need for rigorous donor screening.

Antibiotics

Cons

Pros

High Recurrence Rates: Antibiotic therapy is associated with higher recurrence rates, requiring prolonged and repeated courses.
Disruption of Microbiota: Antibiotics not only target the pathogen but also disrupt the healthy gut microbiota, potentially leading to dysbiosis.
High Long Term Costs: Antibiotics are generally more affordable initially, but antibiotic-related complications, such as adverse reactions, recurrent infections and prolonged hospital stays for extended treatment durations as well as change of antibiotics may cause costs to escalate rapidly.

Widespread Availability: Antibiotics are readily available and can be administered orally or intravenously, ensuring ease of use.
Cost-Effective: Antibiotics are generally more cost-effective in the short term compared to MTT. But this only holds until the first reoccurrence.

Recommended Precautions

Microbiota Transfer Therapy (MTT) is currently the most effective method for treating recurrent Clostridioides difficile infection, capable of restoring natural functionality. When conducted according to professional guidelines and MTT regulations, the procedure is safe. The use of MTT reduces the likelihood of recurrent infections while also improving gut microbiota diversity as a beneficial side effect.

During the MTT treatment period, it is essential to ensure that the patient:
- does not take antibiotics or probiotics;
- consumes foods containing live bacteria (such as live-culture dairy products and lacto-fermented vegetables);
- eats antibiotic- and antihelmint-free animal protein and avoids artificial sweeteners;
- if seeking a stable and long-term solution, visits our farm, Cservölgy Major, which provides food sources for donors:

Known Side Effects

Most clinical studies have shown that after MTT administration, mild side effects (such as abdominal discomfort, diarrhea, constipation, and low-grade fever) may temporarily occur in certain cases. Rare and severe side effects were primarily associated with potential complications related to endoscopy and sedation. [1], [2]

[1] Fecal microbiota transplantation: review and update

[2] Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review

Disclaimer

MicroBiome Bank, when providing the HospBiome and DiffBiome services, neither verifies nor intends to verify the authenticity of the provided identity and/or medical prescription. By placing an order, the customer acknowledges that the laboratory will perform the ordered service under the name provided by the customer, using a donor sample assigned with a laboratory-tested code. The processing is unique, and the final HospBiome and DiffBiome capsules are identifiable and traceable through an assigned code. By ordering HospBiome and DiffBiome capsules, the customer declares that the capsules, labeled "For Physician Use," will be administered under the supervision of their treating physician. Any effects resulting from intentional or unintentional miscommunication or the provision of false information are solely the responsibility of the customer.

Get in Touch

Do you have any questions? Unsure which therapy or service to choose from Microbiome Bank’s offerings? Contact us, and together we’ll find the most suitable solution! We will respond to your message as soon as possible.

Office

MicroBiome Bank Ltd.
2 Brandon Road
Braintree, Essex
CM7 2NL
United Kingdom

Want to Talk?

info@MicroBiomeBank.com

Social Media